Physician profile
Eric A Orzeck
NPI 1356342406
$27,054.20
in general payments reported to CMS, 2019-2025
70 companies · $3,955 in 2025
The $3,955 reported for 2025 was more than what 86% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $9,423 · 2020: $3,205 · 2021: $3,294 · 2022: $2,210 · 2023: $2,061 · 2024: $2,906 · 2025: $3,955.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,908 · Education: $7.96 · Travel and Lodging: $6.63.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,907.62 |
| Education | $7.96 |
| Travel and Lodging | $6.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $5,326.74 | 2019-2025 | Sogroya, Wegovy, Ozempic |
| Amgen INC. | $3,710.75 | 2019-2025 | Evenity, Prolia, Tepezza |
| Lilly USA, LLC | $2,055.06 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Astrazeneca Pharmaceuticals LP | $1,795.60 | 2019-2021 | |
| Mannkind Corporation | $1,133.86 | 2019-2024 | Afrezza |
| Sanofi-Aventis U.S. LLC | $1,132.90 | 2019-2025 | |
| Amarin Pharma, INC. | $863.48 | 2019-2021 | |
| Corcept Therapeutics | $723.76 | 2019-2025 | Korlym |
| Madrigal Pharmaceuticals | $578.90 | 2024-2025 | Rezdiffra, Resmetirom |
| Esperion Therapeutics, INC. | $535.95 | 2021-2025 | Nexletol, Nexlizet |
| Vertex Pharmaceuticals Incorporated | $533.33 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $495.40 | 2019-2024 | Jardiance |
| Abbvie INC. | $473.10 | 2019-2025 | |
| Cequr Corporation | $469.82 | 2021-2025 | Cequr Simplicity |
| Tandem Diabetes Care, INC. | $433.40 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
Show all 70 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Orzeck listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.